摘要
目的分析替吉奥单药化疗联合华蟾素对胃癌晚期不可切除或复发患者的临床治疗疗效及安全性,为胃癌晚期不可切除或复发患者治疗方案选择提供参考。方法选择胃癌晚期不可切除或者胃癌根治术后复发患者共计84例,将其随机分为2组,每组42例,分别采用替吉奥单药化疗、替吉奥联合华蟾素治疗。2组患者均连续治疗4个周期。2组患者完成治疗后分别于1个月、3个月、6个月、12个月、24个月、36个月随访,统计患者的毒副作用,比较2组患者1年、2年、3年生存率、不同阶段的体力状况(KPS)评分、肿瘤患者生活质量评分(QOL)及3年死亡率。结果2组患者肿瘤分期、病理类型、年龄、性别、入组前KPS评分、QOL评分、预估生存期比较差异无统计学意义(P>0.05)。2组患者均完成4个疗程治疗,2组患者1年生存率比较差异无统计学意义(P>0.05);联合治疗组患者2年生存率、3年生存率高于替吉奥组(P<0.05);替吉奥组患者完成治疗后1个月、3个月、6个月、12个月不良反应率明显高于联合治疗组(P<0.05),KPS评分、QOL评分明显高于替吉奥组患者,随访3年,替吉奥组患者死亡率明显高于联合治疗组(P<0.05)。结论替吉奥单药化疗联合华蟾素可有效增加复发或晚期胃癌患者2年期、3年期生存率,降低患者化疗不良反应,提高患者生活质量,降低死亡率,对胃癌不可手术切除患者或者复发患者具有重要的临床价值。
Objective To analyze the clinical efficacy and safety of S-1 chemotherapy combined with cinobufotalin for unresectable or recurrent advanced gastric cancer,and provide treatment options.Methods 84 cases of unresectable or recurrent advanced gastric cancer after radical resection were randomly divided into 2 groups,42 cases in each group,respectively received S-1 chemotherapy,and S-1 combined with cinobufotalin.The 2 groups of patients were treated for 4 cycles.The 2 groups of patients after treatment were follow-uped at 1 month,3 months,6 months,12 months,24 months and 36 months,statistical side effects were collected,compared 1-,2-,3-year survival rates,physical status(KPS)in different stages,the quality of life(QOL)of patients and 3-year mortality.Results There was no significant difference between the 2 groups in tumor stage,pathological type,age,sex,KPS score,QOL score and survival time(P>0.05).The 2 groups of patients were treated with 4 courses of treatment.The 1-year survival rate had no statistically significant difference between the 2 groups(P>0.05);2-and 3-year survival rates of combined treatment group were higher than the S-1 group(P<0.05);1 month,3 months,6 months,12 the months after treatment,toxicity rate of S-1 group was obviously higher than the combined treatment group(P<0.05),KPS score,QOL score of the combined treatment group were significantly higher than those of S-1 group,follow-up of 3 years,the mortality of S-1 group was significantly higher than the combined treatment group(P<0.05).Conclusion S-1 chemotherapy combined with cinobufotalin can effectively increase 2-and 3-year survival rates of recurrent or advanced gastric cancer reduce toxicity of chemotherapy,improve the quality of life of patients,reduce the mortality,and it have clinical value for patients with unresectable or recurrent gastric cancer.
作者
肖荣倩
张颖雪
郭洁
XIAO Rongqian;ZHANG Yingxue;GUO Jie(Nanyang Central Hospital,Nanyang,473000)
出处
《实用癌症杂志》
2021年第1期89-92,共4页
The Practical Journal of Cancer
